This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Implementing the EffTox dose-finding design in the Matchpoint trial
BMC Medical Research Methodology Open Access 20 July 2017
-
Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells
Blood Cancer Journal Open Access 07 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E et al. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma 2013; 54: 2200–2204.
Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012; 118: 3549–3555.
Lemieux E, Hulin C, Caillot D, Tardy S, Dorvaux V, Michel J et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 445–449.
Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI myeloma × relapse (Intensive trial)): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 874–885.
Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011; 86: 640–645.
van de Donk NW, Wittebol S, Minnema MC, Lokhorst HM . Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010; 148: 335–337.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
Thall PF, Cook JD . Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004; 60: 684–693.
Fisher R . On the interpretation of χ2 from contingency tables, and the calculation of P. J R Stat Soc 1922; 85: 87–94.
Freeman GH, Halton JH . Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951; 38: 141–149.
Gelman ACJ, Stern HS, Rubin DB . Bayesian Data Analysis 2nd edn. Chapman & Hall/CRC Press: New York, NY, USA, 2004.
Ibrahim JG, Chen M-H, Sinha D . Bayesian Survival Analysis. Springer: New York, NY, 2001.
Doo NW, Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K et al. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma 2013; 54: 1465–1472.
Orlowski RZ . Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol 2013; 40: 634–651.
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Drs N Shah, Bashir, JJ Shah, Hosing and Orlowski receive research funding from Celgene. Drs N Shah, JJ Shah and Orlowski have served on Celgene Advisory Boards.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Shah, N., Thall, P., Fox, P. et al. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29, 1945–1948 (2015). https://doi.org/10.1038/leu.2015.54
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.54
This article is cited by
-
Implementing the EffTox dose-finding design in the Matchpoint trial
BMC Medical Research Methodology (2017)
-
Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells
Blood Cancer Journal (2016)